Minirin Indications/Uses

Tablet: MINIRIN tablets are indicated for the treatment of central diabetes insipidus. The use of MINIRIN in patients with an established diagnosis will result in a reduction in urinary output with concomitant increase in urine osmolality and decrease in plasma osmolality. This will result in decreased urinary frequency and decreased nocturia.
MINIRIN tablets are indicated for the treatment of primary nocturnal enuresis in children aged 5 years or more.
Oral lyophilisate: MINIRIN oral lyophilisate is indicated for the treatment of central diabetes insipidus.
MINIRIN oral lyophilisate is indicated for the treatment of primary nocturnal enuresis in patients (from 5 years of age) with normal ability to concentrate urine.
Injection & Nasal spray: Central Diabetes Insipidus: The use of Minirin in patients with an established diagnosis will result in a reduction in urinary output with concomitant increase in urine osmolality and decrease in plasma osmolality. This will result in decreased urinary frequency and decreased nocturia.
Renal concentrating capacity test: Minirin can be used to test the capacity of the kidneys to concentrate urine; as a diagnostic aid in the examination of the kidney function. This is especially useful in the differential diagnosis between level of urinary tract infections. Cystitis will opposite to pyelonephritis not cause a subnormal ability to concentrate urine.
Injection: Hemophilia A and von Willebrand's disease: For the therapeutic control of bleeding and bleeding prophylaxis in connection with minor surgical procedures in patients with mild haemophilia A and von Willebrand's disease who respond positively to the test dose. In exceptional cases, even moderate forms of the disease can be treated. MINIRIN must not be used in patients with von Willebrand's disease type II B.